NCT03939026View on ClinicalTrials.gov

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

October 23, 2021

Study Completion Date

August 31, 2026

Conditions
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular Lymphoma
Interventions
GENETIC

ALLO-501

ALLO-501 is an allogeneic CAR T cell therapy targeting CD19

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

Trial Locations (7)

33612

Moffitt Cancer Center, Tampa

40207

Norton Cancer Institute, Louisville

77030

MD Anderson, Houston

78704

St. Davids South Austin Medical Center, Austin

80218

Colorado Blood Cancer Institute, Denver

85234

Banner MD Anderson Cancer Center, Gilbert

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Allogene Therapeutics

INDUSTRY

NCT03939026 - Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma | Biotech Hunter | Biotech Hunter